Interference with the expression of ABCG1 or inhibition of Wnt/β-catenin results in decreased oxaliplatin resistance, supporting a role for these proteins in the acquired drug resistance of HCC. The gene discussed is ABCG1; the disease is hepatocellular carcinoma.